Endocrine Society GUIDELINES Bundle (free trial)

Functional Hypothalamic Amenorrhea

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140181

Contents of this Issue


Page 7 of 7

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2017 All rights reserved Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. ESFHA1772 Î In patients with FHA wishing to conceive, after a complete fertility workup ES suggests: • treatment with pulsatile gonadotropin-releasing hormone (GnRH) as a first line, followed by gonadatropin therapy and induction of ovulation when GnRH is not available (2|⊕ ); • cautious use of gonadotropin therapy (2|⊕ ); • a trial of treatment with clomiphene citrate for ovulation induction if a woman has a sufficient endogenous estrogen level (2|⊕ ); • against the use of kisspeptin and leptin for treating infertility (2|⊕ ); and • given that there is only a single, small study suggesting efficacy but minimal potential for harm, clinicians can consider a trial of CBT in women with FHA who wish to conceive, since this treatment has the potential to restore ovulatory cycles and fertility without the need for medical intervention. (2|⊕⊕ ) Î ES suggests that clinicians should induce ovulation only in women with FHA that have a body mass index (BMI) of at least 18.5 kg/m 2 and only after attempts to normalize energy balance, due to the increased risk for fetal loss, small-for-gestational-age babies, preterm labor, and delivery by Cesarean section for extreme low weight. (2|⊕⊕ ) Treatment Source Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, Murad MH, Santoro NF, Warren MP. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017 May 1;102(5):1413-1439. Cosponsoring Associations: e American Society for Reproductive Medicine, the European Society of Endocrinolog y, and the Pediatric Endocrine Society. Abbreviations 17-OHP, 17-hydroxyprogesterone; AMH, anti-Müllerian hormone; BMD, bone mineral density; BMI, body mass index; CAH, congenital adrenal hyperplasia; CBT, cognitive behavior therapy; DHEA, dehydroepiandrosterone; DHEA-S, dehydroepiandrosterone sulfate; DXA, dualenerg y X-ray absorptiometry; E2, estradiol; ES, Endocrine Society; FHA, functional hypothalamic amenorrhea; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; HPA, hypothalamic–pituitary–adrenal; HPO, hypothalamic–pituitary–ovarian; IGF, insulinlike growth factor; LH, luteinizing hormone; MRI, magnetic resonance imaging ; nl, normal; OCP, oral contraceptive pill; P4, progesterone; PCOS, polycystic ovary syndrome; PRL, prolactin; rPTH, recombinant parathyroid hormone 1-34; T, testosterone; T4, thyroxine; TSH, thyroid-stimulating hormone

Articles in this issue

Links on this page

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Functional Hypothalamic Amenorrhea